Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

by Voloshyna, N, Havrdová, E, Hutchinson, M, Nehrych, T, You, X, Belachew, S, Hotermans, C, Paes, D
Published 2015

Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative...

by Rup, B, Pallardy, M, Sikkema, D, Albert, T, Allez, M, Broet, P, Carini, C, Creeke, P, Davidson, J, De Vries, N, Finco, D, Fogdell-Hahn, A, Havrdova, E, Hincelin-Mery, A, C Holland, M, H Jensen, P E, Jury, E C, Kirby, H, Kramer, D, Lacroix-Desmazes, S, Legrand, J, Maggi, E, Maillère, B, Mariette, X, Mauri, C, Mikol, V, Mulleman, D, Oldenburg, J, Paintaud, G, R Pedersen, C, Ruperto, N, Seitz, R, Spindeldreher, S, Deisenhammer, F
Published 2015